Squarepoint
ABBV icon

Squarepoint’s AbbVie ABBV Stock Holding History

Squarepoint’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.1M Sell
55,600
-93,100
-63% -$20.7M 0.01% 975
2025
Q4 		$34M Buy
148,700
+60,000
+68% +$13.7M 0.04% 540
2025
Q3 		$20.5M Sell
88,700
-126,200
-59% -$25.7M 0.02% 732
2025
Q2 		$39.9M Sell
214,900
-43,000
-17% -$7.99M 0.04% 464
2025
Q1 		$54M Buy
257,900
+40,500
+19% +$7.87M 0.07% 324
2024
Q4 		$38.6M Buy
217,400
+100,800
+86% +$18.5M 0.04% 472
2024
Q3 		$23M Sell
116,600
-3,900
-3% -$728K 0.04% 534
2024
Q2 		$20.7M Sell
120,500
-263,800
-69% -$43.7M 0.03% 566
2024
Q1 		$70M Buy
384,300
+268,200
+231% +$46.2M 0.12% 161
2023
Q4 		$18M Buy
116,100
+101,300
+684% +$14.8M 0.03% 615
2023
Q3 		$2.21M Sell
14,800
-15,500
-51% -$2.28M 0.01% 1735
2023
Q2 		$4.08M Buy
30,300
+17,800
+142% +$2.61M 0.01% 1188
2023
Q1 		$1.99M Sell
12,500
-30,000
-71% -$4.59M 0.01% 1418
2022
Q4 		$6.87M Buy
42,500
+32,600
+329% +$5M 0.03% 675
2022
Q3 		$1.33M Sell
9,900
-7,400
-43% -$1.06M 0.01% 1575
2022
Q2 		$2.65M Buy
17,300
+12,200
+239% +$1.86M 0.01% 1020
2022
Q1 		$827K Sell
5,100
-5,600
-52% -$813K ﹤0.01% 1701
2021
Q4 		$1.45M Sell
10,700
-2,500
-19% -$295K ﹤0.01% 1458
2021
Q3 		$1.42M Sell
13,200
-32,000
-71% -$3.66M ﹤0.01% 1368
2021
Q2 		$5.09M Sell
45,200
-9,500
-17% -$1.07M 0.02% 718
2021
Q1 		$5.92M Buy
54,700
+32,900
+151% +$3.52M 0.03% 557
2020
Q4 		$2.34M Buy
21,800
+19,300
+772% +$1.85M 0.02% 864
2020
Q3 		$219K Buy
2,500
+200
+9% +$18.8K ﹤0.01% 2028
2020
Q2 		$226K Buy
+2,300
New +$203K ﹤0.01% 1764
2020
Q1 		– Sell
-2,800
Closed -$248K – 1793
2019
Q4 		$248K Sell
2,800
-12,800
-82% -$1.06M ﹤0.01% 2127
2019
Q3 		$1.18M Buy
15,600
+11,300
+263% +$775K 0.01% 1111
2019
Q2 		$313K Buy
4,300
+200
+5% +$15.7K ﹤0.01% 1916
2019
Q1 		$330K Buy
+4,100
New +$335K ﹤0.01% 1722

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint's ABBV Position: Q1 2026 in Review

Squarepoint increased its AbbVie (ABBV) stake by 160% in Q1 2026, buying an estimated $26.5M and bringing the position to 193,871 shares worth $42.2M. The position accounts for 0.05% of the portfolio, ranked #384.

Squarepoint first reported a position in ABBV in Q3 2015 and has held it in 31 quarters since. The position peaked at $92.1M in Q2 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Squarepoint held 193,871 shares of AbbVie worth $42.2M as of Q1 2026.
  • Squarepoint bought 119,297 AbbVie shares in Q1 2026, an estimated $26.5M.
  • AbbVie made up 0.05% of Squarepoint's portfolio in Q1 2026, its #384 holding.
  • Squarepoint first reported a position in AbbVie in Q3 2015 and has held it in 31 quarters since.
  • Squarepoint's AbbVie position peaked at $92.1M in Q2 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.